796 related articles for article (PubMed ID: 19303722)
1. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
2. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
3. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
4. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.
Rouissi K; Ouerhani S; Marrakchi R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Cancer Genet Cytogenet; 2009 Apr; 190(2):101-7. PubMed ID: 19380028
[TBL] [Abstract][Full Text] [Related]
5. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population.
Hung RJ; Boffetta P; Brennan P; Malaveille C; Hautefeuille A; Donato F; Gelatti U; Spaliviero M; Placidi D; Carta A; Scotto di Carlo A; Porru S
Int J Cancer; 2004 Jul; 110(4):598-604. PubMed ID: 15122594
[TBL] [Abstract][Full Text] [Related]
6. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
[TBL] [Abstract][Full Text] [Related]
7. CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a Turkish population.
Berber U; Yilmaz I; Yilmaz O; Haholu A; Kucukodaci Z; Ates F; Demirel D
Asian Pac J Cancer Prev; 2013; 14(6):3925-9. PubMed ID: 23886208
[TBL] [Abstract][Full Text] [Related]
8. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk.
Zhao H; Lin J; Grossman HB; Hernandez LM; Dinney CP; Wu X
Int J Cancer; 2007 May; 120(10):2208-13. PubMed ID: 17290402
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis.
Kim WJ; Lee HL; Lee SC; Kim YT; Kim H
J Urol; 2000 Jul; 164(1):209-13. PubMed ID: 10840461
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
McGrath M; Michaud D; De Vivo I
BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
[TBL] [Abstract][Full Text] [Related]
11. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
12. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
[TBL] [Abstract][Full Text] [Related]
13. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls.
Nyberg F; Hou SM; Hemminki K; Lambert B; Pershagen G
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):875-83. PubMed ID: 9796632
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.
Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Gimenez-Bachs JM; Lorenzo-Romero JG; Serrano-Oviedo L; Escribano J
BJU Int; 2011 Jun; 107(11):1825-32. PubMed ID: 20942828
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-transferase (GST) M1, T1 and N-acetyltransferase 2 (NAT2) polymorphisms and urothelial cancer risk with tobacco smoking.
Tsukino H; Nakao H; Kuroda Y; Imai H; Inatomi H; Osada Y; Katoh T
Eur J Cancer Prev; 2004 Dec; 13(6):509-14. PubMed ID: 15548945
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China.
Chen HC; Cao YF; Hu WX; Liu XF; Liu QX; Zhang J; Liu J
Dis Markers; 2006; 22(3):141-52. PubMed ID: 16788248
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.
Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E
Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921
[TBL] [Abstract][Full Text] [Related]
18. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls.
Hou SM; Fält S; Yang K; Nyberg F; Pershagen G; Hemminki K; Lambert B
Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):133-40. PubMed ID: 11219770
[TBL] [Abstract][Full Text] [Related]
19. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
Moore LE; Baris DR; Figueroa JD; Garcia-Closas M; Karagas MR; Schwenn MR; Johnson AT; Lubin JH; Hein DW; Dagnall CL; Colt JS; Kida M; Jones MA; Schned AR; Cherala SS; Chanock SJ; Cantor KP; Silverman DT; Rothman N
Carcinogenesis; 2011 Feb; 32(2):182-9. PubMed ID: 21037224
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
